Northwest Biotherapeutics (NWBO) Share-based Compensation (2010 - 2026)

Northwest Biotherapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $288000.0 for Q1 2026.

• On a quarterly basis, Share-based Compensation fell 25.19% year-over-year to $288000.0 in Q1 2026; TTM through Mar 2026 was $1.1 million, a 367.47% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 231.59% from the prior year.
• Share-based Compensation grew to $288000.0 in Q1 2026 per NWBO's latest filing, from $185000.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $5.8 million in Q2 2022 and bottomed at -$2.0 million in Q3 2024.
• The 5-year median for Share-based Compensation is $775000.0 (2022), against an average of $1.2 million.
• Biggest YoY gain for Share-based Compensation was 314.75% in 2024; the steepest drop was 220.41% in 2024.
• Year by year, Share-based Compensation stood at $2.6 million in 2022, then sank by 38.4% to $1.6 million in 2023, then plunged by 224.0% to -$2.0 million in 2024, then surged by 109.47% to $185000.0 in 2025, then jumped by 55.68% to $288000.0 in 2026.
• Per Business Quant, the three latest NWBO Share-based Compensation figures stand at $288000.0 (Q1 2026), $185000.0 (Q4 2025), and $273000.0 (Q3 2025).